Viking Therapeutics Inc [VKTX] stock is trading at $34.32, up 2.57%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VKTX shares have gain 4.41% over the last week, with a monthly amount drifted -18.96%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, B. Riley Securities started tracking the stock with Buy rating on November 22, 2024, and set its price target to $109. On November 04, 2024, H.C. Wainwright reiterated its Buy rating and revised its price target to $102 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $80 on September 11, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $105 as its price target on June 27, 2024. Raymond James upgraded its rating to Strong Buy for this stock on May 16, 2024, and upped its price target to $116. In a note dated March 26, 2024, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $116 to $138.
Viking Therapeutics Inc [VKTX] stock has fluctuated between $21.26 and $99.41 over the past year. Currently, Wall Street analysts expect the stock to reach $98 within the next 12 months. Viking Therapeutics Inc [NASDAQ: VKTX] shares were valued at $34.32 at the most recent close of the market. An investor can expect a potential return of 185.55% based on the average VKTX price forecast.
Analyzing the VKTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.29% with Operating Profit Margin at -307.27%, Pretax Profit Margin comes in at -227.41%, and Net Profit Margin reading is -227.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.13 and Total Capital is -0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.15 points at the first support level, and at 31.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.12, and for the 2nd resistance point, it is at 35.91.
Ratios To Look Out For
For context, Viking Therapeutics Inc’s Current Ratio is 36.47. Further, the Quick Ratio stands at 36.47, while the Cash Ratio is 1.96.
Transactions by insiders
Recent insider trading involved Lian Brian, President & CEO, that happened on Jan 06 ’25 when 0.19 million shares were sold. Chief Operating Officer, Mancini Marianna completed a deal on Jan 06 ’25 to sell 54215.0 shares. Meanwhile, Chief Financial Officer ZANTE GREG sold 50309.0 shares on Jan 06 ’25.
